ABSTRACT
INTRODUCTION R
ENAL CELL CARCINOMA (RCC) is considered to be one of the few immunogenic tumor entities. In some patients, par-tial or complete remission was observed after treatment with various forms of immunotherapy. Studies on allogeneic stem cell transplantation have shown partial success in treating metastatic RCC (Childs et al., 2000; Ueno et al., 2003) . Adoptive T cell transfer has proved effective for the treatment of cytomegalovirus (CMV) disease, Epstein-Barr virus-positive (EBV ϩ ) lymphoma, and leukemia (Kolb et al., 1990; Rooney et al., 1995; Walter et al., 1995) . Preliminary studies indicate that adoptive T cell therapy also has potential for melanoma treatment (Dudley et al., 2002) . Treatment of other cancer entities via adoptive transfer is difficult for several reasons. The poor immunogenicity of many tumors is one reason, as it leads to difficulty in isolating tumor-reactive cytotoxic T lymphocytes (CTLs) from tumors. This occurs because of low numbers of tumor-infiltrating lymphocytes (TILs) or their poor state of reactivity (tolerogenic T cells). For adoptive transfer, TILs need to be amplified to large numbers, which is often not feasible. The genetic redirection of patient peripheral blood lymphocytes (PBLs) toward a desired reactivity is a promising approach to overcome these problems. The successful modification of PBL specificity through retroviral transfer of T cell receptor (TCR) or chimeric antibody receptor genes has been shown (reviewed in Eshhar, 1997; Hombach et al., 2002; Schumacher, 2002) . With regard to human tumor-associated antigens, however, only TCRs recognizing melanoma or a minor histocompatibility antigen have so far been transferred into human PBLs (MART-1 [Clay et al., 1999] , gp100 [Schaft et al., 2003] , and mHag HA-2 [Heemskerk et al., 2003] ). Here we describe the generation of RCC-specific CTLs by TCR ␣ and ␤ chain transfer. The TCR is derived from a cloned TIL line isolated from an RCC patient (Schendel et al., 1993) . It recognizes a yet unknown RCC tumor antigen in an HLA-A*0201-restricted manner (Jantzer and Schendel, 1998) . For transfer, the TCR was cloned into two different retroviral vectors: a Moloney murine leukemia virus (MLV) vector and a vector optimized for gene transfer into T lymphocytes (MP71) (Engels et al., 2003) . The LXSN-based vector is a MLV-derived vector (Miller and Rosman, 1989 ) that has been used as a basis for several more advanced MLV vectors (MFG [Dranoff et al., 1993] ).The optimized vector MP71 contains several cis-regulatory elements that drive high-level and long-lasting transgene expression in primary T lymphocytes. Strong transgene expression is mandatory in many settings where the amount of expressed protein directly correlates with function, as, for example, in the case of TCRs (Labrecque et al., 2001; Heemskerk et al., 2004) . In this study, we show successful expression of a TCR recognizing an as yet unidentified RCC antigen on retrovirally transduced PBLs. The redirected T lymphocytes express sufficient amounts of the TCR to mount effector functions on specific stimulation, which are similar in magnitude to those seen with the original TIL clone.
MATERIALS AND METHODS

Cell lines and primary cells
293-10A1 packaging cells (Farson et al., 1999) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS; Greiner, Frickenhausen, Germany) . The human T cell line HuT78 (TIB161; American Type Culture Collection [ATCC] , Manassas, VA), a CD4 ϩ cutaneous T cell lymphoma line, was cultured in RPMI 1640 medium with 10% FCS, 10 mM HEPES, and 2 mM glutamine. The proerythroleukemic cell line K-562 (CCL-243; ATCC) and the Burkitt's lymphoma cell line Daudi (CCL-213; ATCC) were cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 1 mM sodium pyruvate, and penicillin-streptomycin (100 U/ml) ("standard growth medium"). The following cell lines were established from RCC patients and cultured in standard growth medium: NKC-26, SV40 large T antigen-transformed normal kidney cells of patient 26; LCL-26, an EBV-transformed B-lymphoblastoid cell line of patient 26; and RCC-26 and RCC-53, renal cell carcinoma tumor cells of patients 26 and 53, respectively. TIL-26, a tumor-infiltrating lymphocyte clone of patient 26 (Schendel et al., 1993) , was cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 7.5% heat-inactivated FCS, 7.5% heat-inactivated pooled human serum, and recombinant human interleukin 2 (rhIL-2; 50 U/ml) (Roche Applied Science, Mannheim, Germany). TIL-26 cells were stimulated bimonthly with irradiated (100 Gy, using as 137 Cs source a Gammacell 40, Atomic Energy of Canada, Ottawa, ON, Canada) IL-2-secreting autologous RCC-26 cells (Pohla et al., 2000) , irradiated (50 Gy) pooled allogeneic peripheral blood mononuclear cells (PBMCs), and irradiated (150 Gy) EBVtransformed allogeneic B-LCL. Fresh medium was given biweekly and TILs were split when cells were confluent. For functional assays measuring antigen-specific cytotoxicity or induction of cytokine secretion TILs were used on days 7 and 14, respectively, after the last stimulation. Human peripheral blood lymphocytes (PBLs) were isolated from healthy donors by Ficoll gradient centrifugation (Seromed-Biochrom, Berlin, Germany) and stimulated for 72 hr with rhIL-2 (50 U/ml) and immobilized anti-CD3 and anti-CD28 monoclonal antibodies (mAbs; BD Biosciences Pharmingen, San Diego, CA) as described (Uckert et al., 2000) . PBLs were cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 10 mM HEPES, penicillin-streptomycin (100 U/ml), and rhIL-2 (10 U/ml), if not stated differently. For monthly restimulation 2 ϫ 10 5 PBLs were seeded into a well of a 24-well plate. PBMCs (3.2 ϫ 10 6 ) from two donors, irradiated with 30 Gy, rhIL-2 (50 U/ml), and anti-CD3 mAb (30 ng/ml), were added to the wells. All tissue culture media and additives were purchased from GIBCO (Karlsruhe, Germany).
Construction of retroviral vectors and production of viral supernatants
TCR ␣ and ␤ chains were derived from a TIL clone isolated from RCC patient 26 (TIL-26; V ␣ 20-J ␣ 22 [TRAV4*01-TRAJ22*01] and V ␤ 22-J ␤ 2.7 [TRBV2*03-TRBJ2-7*01], respectively; Jantzer and Schendel, 1998) . Total RNA was isolated with RNA-Bee (Tel-Test, Friendswood, TX). After the generation of cDNA by random primers and Moloney murine leukemia virus reverse transcriptase (M-MLV-RT; USB, Cleveland, OH), the chains were amplified with oligonucleotides V␣20sal sense (5Ј-GTC GTC GAC CAC CAT GAG GCA AGT G-3Ј), C␣xho antisense (5Ј-CAC TCG AGT CAG CTG GAC CAC AGC-3Ј), V␤22not sense (5Ј-CGT GCG GCC GCC ACC ATG GAT ACC TGG C-3Ј), and C␤xba antisense (5Ј-GCA TCT AGA CTA GCC TCT GGA ATC CTT TCT CTT G-3Ј). They were subsequently cloned into the plasmid pPBS, containing the poliovirus internal ribosomal entry site (IRES, kindly provided by W.F. Anderson) (Morgan et al., 1992) , to obtain pPBS␤IRES␣. The ␤IRES␣ fragment including the Kozak sequence was then cloned into two retroviral vectors. The vector plasmid pL␤IRES␣ (pL-tcr, 7235 bp) is a derivative of pLXSN (Miller and Rosman, 1989) . For the construction of pL-tcr the simian virus 40 promoter (S) and the neomycin resistance gene (N) were excised from pLXSN by HpaI and NaeI digestion (all restriction enzymes were purchased from Amersham Biosciences/GE Healthcare, Freiburg, Germany) and replaced by the ␤IRES␣ fragment, obtained by XhoI restriction of pPBS␤IRES␣, followed by incubation with Klenow fragment (USB) and a final NotI digestion. The vector plasmid pMP71␤IRES␣PRE (pMP-tcr, 7893 bp) is based on pMP71GPRE (Engels et al., 2003) . For the development of pMP-tcr, pMP71GPRE was partially digested with EcoRI, in order to maintain the posttranscriptional regulatory element (PRE). After incubation with Klenow fragment the vector was digested with NotI and the ␤IRES␣ fragment, excised as described above, was inserted into the vector. The green fluorescent protein (GFP)-encoding vector pMP71GPRE was used as a mock control throughout this study, and is named pMP-gfp.
Stable producer cell clones were generated by cotransfection of 293-10A1 packaging cells with either of the retroviral vector plasmids and the plasmid pWLneo (Stratagene, Heidelberg, Germany), using calcium phosphate precipitation (Amersham Pharmacia Biotech) (Uckert et al., 2000) . High-titer virus vector particle-containing supernatant (viral supernatant) was produced in 175-cm 2 tissue culture flasks (Corning Costar, Bodenheim, Germany) at 37°C and stored in aliquots at Ϫ80°C.
Transduction of T cells
HuT78 cells and stimulated PBLs were transduced in 24-well non-tissue culture plates coated with RetroNectin (TaKaRa Bio, Otsu, Japan) as described (Uckert et al., 2000) . HuT78 cells (1 ϫ 10 5 per well, and per ml) or PBLs (2 ϫ 10 5 per well, and per ml) were transduced for 24 hr with 1 ml of viral supernatant supplemented with protamine sulfate (4 g/ml; Sigma-Aldrich Chemie, Munich, Germany). For PBLs, rhIL-2 (50 U/ml) was added. Cells were then transferred to culture flasks and cultured as described above.
Flow cytometric analysis and magnetic cell sorting
Cells were stained with fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated anti-TCR chain V ␤ 22 mAb (Serotec, Oxford, UK) or with anti-CD3, anti-CD4, or anti-CD8 mAb (BD Biosciences Pharmingen). Data acquisition and analysis was performed on a FACSCalibur (BD Biosciences Immunocytometry Systems, San Jose, CA) using CellQuest Pro software.
To enrich for V ␤ 22-positive cells, MP-tcr-transduced PBLs were stained with PE-conjugated anti-V ␤ 22 mAb and subsequently with anti-PE microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). The stained cells were thereafter purified with an autoMACS separator (Miltenyi Biotec) according to the manufacturer's instructions.
Genomic DNA polymerase chain reaction
Genomic DNA (gDNA) was isolated from L-tcr-, MP-tcr-, and nontransduced PBLs on days 11 and 32 posttransduction, using a DNeasy tissue kit (Qiagen, Hilden, Germany), and subsequently treated with DNase-free RNase (Roche Applied Science). One hundred nanograms and 10 ng of gDNA were employed for each sample. Forward primer fvb-c (5Ј-GCA GAA CCC CCG CAA CCA CT-3Ј) and reverse primer rIRES (5Ј-CGA CAT CAC CGG GGA AAC AGA AG-3Ј) were used to amplify a vectorspecific 450-bp product. As loading control glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific primers were used to generate a 451-bp product (forward primer, 5Ј-ACC ACA GTC CAT GCC ATC AC-3Ј; reverse primer, 5Ј-TCC ACC ACC CTG TTG CTG TA-3Ј). PCRs were run in a T personal thermocycler (Biometra, Göttingen, Germany) using Taq DNA polymerase (Invitrogen, Karlsruhe, Germany). PCR conditions were 2 min at 94°C; 25, 30, or 35 cycles of 94°C for 30 sec; 68°C for 30 sec and 72°C for 1 min; and a final 10-min incubation at 72°C for the virus-specific reaction, and with an annealing temperature of 55°C for GAPDH. PCR products were analyzed by 1% agarose gel electrophoresis, ethidium bromide staining, and quantification with the Lumi-Imager F1 and LumiAnalyst software (both from Roche Applied Science).
Reverse transcription-polymerase chain reaction
Total RNA was isolated from PBLs on days 11 and 32 posttransduction with either L-tcr or MP-tcr according to Chomczynski and Sacchi (1987) . RNA concentration was determined spectrophotometrically after RNase-free DNase I digestion (Roche Applied Science). cDNA was synthesized using 1 g of total RNA, random primers, and reverse transcriptase (RT; both from Invitrogen) in a 20-l reaction mix. A 0.5-or 0.1-l volume of cDNA was used per PCR. As negative controls no-template and no-RT samples were included. Reactions were run in a Tpersonal thermocycler using Taq DNA polymerase. The same primers and PCR conditions as for gDNA PCR were used. PCR products were analyzed by 1% agarose gel electrophoresis, ethidium bromide staining, and quantification with the Lumi-Imager F1 and LumiAnalyst software.
Cytokine release assay
Target cells (1.5 ϫ 10 4 ) were cocultured with 1.0 ϫ 10 4 PBLs or 3.0 ϫ 10 3 TIL-26 cells in 96-well round-bottom plates for 24 hr. The supernatant was removed and tested for interferon ␥ (IFN-␥) and tumor necrosis factor ␣ (TNF-␣) content by enzyme-linked immunosorbent assay (ELISA) (sensitivity, 4 pg/ml; eBioscience, San Diego, CA) according to the manufacturer's protocol. Inhibition assays were performed by adding MA2.1 (anti-HLA-A2 mAb, 4 g/well; ATCC HB-54), W6/32 (anti-MHC class I Ab, 2 g/well; ATCC HB-95), or MOPC21 (mouse IgG1 isotype control, 4 g/well; Sigma) during cocultivation. K-562 and Daudi cells, which lack MHC class I molecules, were used as negative controls for stimulation, and anti-CD3 mAb (BD Biosciences Pharmingen)-coated wells (5 g/ml) were used as a positive control. The data are given as mean values with standard deviations of duplicates, derived from one representative experiment. At least two independent experiments were performed.
Cytotoxicity assay
Cell-mediated lysis of target cells by T cell clone TIL-26 and TCR gene-modified PBLs was quantified in a 4-hr 51 Cr release assay. Effector-to-target cell ratios ranged from 20:1 to 1.25:1, employing 2.0 ϫ 10 3 target cells. Spontaneous release was determined by incubating target cells alone, and the maximal release was determined by directly counting labeled cells. The percentage of cytotoxicity was calculated as: percent specific lysis ϭ [(cpm experimental Ϫ cpm spontaneous )/(cpm maximal Ϫ cpm spontaneous )] ϫ 100. Duplicate measurements of four-step titration of effector cells were used for all experiments. K-562 and Daudi cells were used as controls. Results shown represent mean values and standard deviations from one of two independent experiments.
RESULTS
Expression of RCC-specific TCR in T cell lines and primary human T lymphocytes is superior with MPSV-based vector
Rearranged TCR ␣ and ␤ chains from TIL-26 were cloned into MLV (pLXSN)-and MPSV (pMP71)-based vectors and named L-tcr and MP-tcr, respectively (Fig. 1A ). Viral supernatants containing either vector were used to transduce HuT78 T cells and primary T lymphocytes of three different donors.
Surface expression of the exogenous TCR was analyzed by flow cytometry using an anti-TCR chain V ␤ 22 mAb. Both the L-tcr and MP-tcr vectors led to transgene expression in HuT78 cells (Fig. 1B) . However, a difference could be seen in the percentage of V ␤ 22-expressing T cells and also in the level of TCR surface expression, measured as mean fluorescence intensity (MFI). Forty-six percent of L-tcr-transduced T cells expressed V ␤ 22 with an MFI of 44, whereas 83% of MP-tcr-transduced T cells expressed V ␤ 22 with an MFI of 74. Such an expression pattern was observed in several experiments (data not shown). The difference in transgene expression by the two vectors was even more pronounced in transduced primary T lymphocytes, where only MP-tcr led to strong TCR expression. In the experiment shown in Fig. 1B , transduction of PBLs of donor 1 with MP-tcr yielded 52% V ␤ 22-positive cells, compared with 7% obtained with L-tcr. This finding was confirmed in several experiments performed at different times with three different donors ( Table 1) 
Both vectors transduce PBLs at similar rates
PBLs were transduced with viral supernatants harvested from producer cell clones selected for high viral titer production. As neither of the vectors contains a selectable marker and therefore titration by transduction of indicator cells was not possible, the relative titer was determined through analysis of copy number integrations. Hence gDNA was prepared from L-tcr-, MP-tcr-, and nontransduced PBLs of two donors on days 11 and 32 posttransduction. PCRs specific for the viral genomes were performed, and the bands were subsequently quantified. The amount of gDNA employed per reaction (100 and 10 ng) was confirmed by GAPDH-specific amplification. Furthermore, PCR samples were analyzed after 25, 30, and 35 cycles of amplification, altogether giving comparable results. In Fig To further analyze the discrepancy between similar viral copy integration and differing TCR expression in L-tcr-and MP-tcr-transduced PBLs, we performed RT-PCR analysis. Total RNA was isolated from L-tcr-, MP-tcr-, and nontransduced PBLs of two donors on days 11 and 32 posttransduction. For RT-PCR we employed two different cDNA amounts, using the same virus-and GAPDH-specific primers described above. Unlike the gDNA PCR, the RT-PCR showed a clear difference in the amount of TCR transcripts between L-tcr-and MP-tcr-transduced PBLs. One experiment representative of two for donor 1 is shown in Fig. 2C and the respective bar diagram is shown in Fig. 2D . For days 11 and 32 posttransduction more TCR-encoding transcript could be detected in MP-tcr-transduced PBLs compared with L-tcr-transduced T cells. On the basis of GAPDH-corrected virus band intensities, a 4-fold higher amount of TCR transcripts was found for MP-tcr-transduced ENGINEERING RCC-REACTIVE CTLs 803 
Redirected PBLs are stimulated by RCC-26 cells
To assess the function of virally expressed TCR, we performed stimulation assays. L-tcr-, MP-tcr-, and nontransduced PBLs of three different donors were cocultured with the tumor cell line RCC-26, which expresses the peptide-MHC ligand for the transgenic TCR. Secretion of IFN-␥ reflected stimulation of the T cells by RCC-26 cells. Shown are representative results obtained for PBLs of donor 1 (Fig. 3) . MP-tcr-transduced PBLs were clearly activated by RCC-26 cells (IFN-␥, 1421 pg/ml). In contrast, L-tcr-transduced PBLs secreted less IFN-␥, in fact only slightly more than did nontransduced PBLs (304 versus 244 pg/ml). The general ability of all cells to be activated and to secrete cytokines was proven by unspecific, redirected stimulation (anti-CD3 mAb, data not shown). The marginal increase in IFN-␥ secretion by L-tcr-transduced PBLs, compared with nontransduced cells, may indicate that the TCR expression by L-tcr is not sufficient to trigger TCR-mediated T cell stimulation. The MPtcr-encoded tumor-specific TCR was, however, expressed at levels sufficient to induce activation of the transduced T cells on cocultivation with the RCC-26 cell line. Referring to the flow cytometric analysis, the higher percentage of V ␤ 22-positive cells allowed activation of the MP-tcr-transduced PBL population. As hardly any TCR-related activity was detected for L-tcr-transduced PBLs, all further experiments were conducted with MPtcr-transduced T cells only.
Redirected PBLs are stimulated by target cells as efficiently as the original TIL clone
The comparison of MP-tcr-transduced PBLs with the original TIL-26 cells, both carrying the same TCR, revealed similar responses to RCC-26 cells. In this assay, the number of effector cells was adjusted on the basis of the percentage of V ␤ 22-positive cells. According to flow cytometry analysis on the day of assay, one-third of the transduced PBLs were V ␤ 22 positive, compared with 100% of the TIL-26 cells (data not shown). Therefore, we employed 1 ϫ 10 4 MP-tcr-transduced PBLs or 3 ϫ 10 3 TIL-26 cells per well. The production of IFN-␥ and TNF-␣ on stimulation of the cells of three different donors showed that TCR-26 gene-modified PBLs developed a similar cytokine response as TIL-26 cells, which express the same TCR endogenously (Fig. 4) . The MP-tcr-transduced PBLs of donor 1 secreted, per milliliter, 1790 pg of IFN-␥ and 230 pg of TNF-␣, whereas TIL-26 cells secreted 1850 pg of IFN-␥ and 260 pg of TNF-␣ (Fig. 4A and B) . The similar amount of both cytokines secreted by each V ␤ 22-positive T cell population argues for physiological TCR transgene expression in the transduced PBLs. MP-gfp-and nontransduced PBLs did not respond to RCC-26 cell stimulation. All cells, however, responded similarly to redirected stimulation with anti-CD3 mAb (data not shown).
Using a set of different target cells, the specificity of redirected PBLs was investigated. MP-tcr-transduced PBLs were not stimulated by the allogeneic renal cell carcinoma cell line RCC-53, the autologous normal kidney cell line NKC-26, or the autologous lymphoblast cell line LCL-26, which are all negative for the peptide-MHC ligand for the transgenic TCR, or by Daudi cells, which are MHC class I negative ( Fig. 4C and D, solid columns). This indicated antigen-specific recognition by the transgenic T cells. Furthermore, the redirected PBLs showed the same specificity as seen for the TIL-26 clone ( Fig.  4C and D, open columns) .
Antigen-specific recognition by redirected PBLs is HLA-A2 restricted
To further confirm specific TCR peptide-MHC interaction resulting in cytokine secretion, we performed blocking assays with various antibodies (Fig. 5) . Using the HLA-A2-specific mAb MA2.1 as a blocking reagent, 81% less IFN-␥ was produced by RCC-26 cell-stimulated MP-tcr-transduced PBLs of donor 1. When the anti-MHC class I antibody W6/32 was used, 95% less IFN-␥ was secreted. The isotype control mAb (MOPC21) did not reduce the amount of IFN-␥ secretion. A similar pattern of blocking was also observed for coculture of RCC-26 cells with additional TCR-transduced PBLs of two donors and the TIL-26 clone that expresses the TCR naturally (data not shown). These data demonstrate that the stimulation of transduced PBLs was based on TCR-mediated recognition of an HLA-A2-restricted RCC tumor antigen, as has been shown for the original TIL-26 cells (Schendel et al., 1997; Jantzer and Schendel, 1998) . positive cell population for donor 1 (Fig. 6A) . Enriched MPtcr-transduced PBLs and the original TIL-26 clone lysed RCC-26 cells to similar extent (Fig. 6B) . Thus, as has been observed for the cytokine response, MP-tcr-transduced PBLs had antitumor activity comparable to that of TIL-26 cells. Mock-transduced and nontransduced PBLs showed similar low background lysis.
Redirected PBLs and TIL-26 cells show similar lytic activity against RCC-26 cells
The specificity of the lysis reaction was shown by incubating the same effector cells with different target cells (Fig.  6C) . Again, no reactivity toward autologous control cells, that is, NKC-26 and LCL-26 cells, was measured, nor were RCC-53 cells lysed. The MHC class I-negative K-562 line, which is a control for natural killer cell activity, was also not lysed. Mock-transduced and nontransduced PBLs exhibited some degree of lytic activity against RCC-26 cells. Because a similar level of activity was observed against MHC class I-negative Daudi cells (data not shown) it is most likely that this activity is nonspecific, induced by exposing PBLs to IL-2 and anti-CD3/anti-CD28 mAbs before retroviral transduction. The pattern of lytic activity, in particular the clear distinction of RCC-26 cells from normal kidney cells, demonstrated that the transduced PBLs specifically lysed cells that present the tumor epitope specific for the transgenic TCR.
MP-tcr-driven TCR expression is stable over time
After expression and function of the transferred TCR-26 cells were shown for MP-tcr-transduced PBLs, the duration of transgene expression was analyzed. In two independent experiments, each with two donors, PBLs transduced with the MP-tcr or the L-tcr vector were cultured in vitro for up to 111 days and V ␤ 22 expression was monitored over time. To maintain the cultures, transduced cells were unspecifically restimulated with irradiated feeder cells and anti-CD3 mAb every 30 days. MP-tcr-, Ltcr-, and nontransduced PBLs proliferated similarly at each round of stimulation (data not shown). Flow cytometry data obtained for transduced PBLs of donor 1 on days 5 and 111 posttransduction show 18 and 15% for MP-tcr, respectively, and 6 and 3% for L-tcr, respectively, of V ␤ 22-positive cells (Fig. 7A) . In cells retained TCR-26 expression. These data clearly indicate that transgene expression by MP-tcr is stable over time, whereas it decreases when using L-tcr. Further analysis of the long-term in vitro-cultured cells showed that TCRs were still functionally active on day 55 posttransduction as indicated by IFN-␥ release (data not shown), similar to those of cells used 14 days posttransduction (Fig. 3) . Taken together, the MP-tcr vector guarantees high transgene expression over more than 100 days, whereas the L-tcr vector fails to express the TCR at high and constant levels.
DISCUSSION
In this study we show the transfer of antitumor specificity from a TIL clone established from an RCC patient to PBLs of healthy donors. Redirected T lymphocytes stably expressed the TCR on the cell surface, were specifically activated by RCC-26 tumor cells as shown by cytokine secretion on coculture, and gained similar killing capabilities as the originally isolated TIL clone. To transfer the TCR genes, we employed two different retroviral vectors: a Moloney murine leukemia virus (MLV)-derived vector (LXSN) (Miller and Rosman, 1989) and an MPSV-derived vector (MP71) (Schambach et al., 2000) . With both, we generated MLV-10A1-pseudotyped vector particles to efficiently transduce PBLs (Uckert et al., 2000) . The optimized MPSV-based vector (MP-tcr) yielded strong and durable TCR expression associated with the ability to perform effector function, whereas the MLV vector (L-tcr) failed to express sufficient amounts of TCR to exert effector function.
These results confirm and extend previous data describing approximately 20-fold higher expression levels of a cytoplasmic protein (GFP) in primary human T lymphocytes transduced with MP71 (MP-gfp) in comparison with LXSN (Engels et al., 2003) . The stronger expression obtained with MP-gfp was not due to multiple integration events, but could clearly be ascribed to the stronger cis-regulatory elements of the MP-gfp vector, as demonstrated by Southern blot and RT-PCR analysis. Now we demonstrate that the MPSV vector also performs better than the MLV vector when used to express a complex multimeric protein such as a TCR, which consists of ␣ and ␤ chain proteins and requires additional proteins of the CD3 complex for transport to the cell surface. To exclude that the higher TCR expression level obtained with MP-tcr compared with L-tcr was due to higher viral titers and consequently multiple integrations, we employed the most objective criteria for titer estimation and analyzed the number of integrated viral copies in the transduced T cells. Both MP-tcr-and L-tcr-transduced T lymphocyte populations revealed similar amounts of integrated vector genomes, as shown by semiquantitative DNA PCR and real-time PCR (data not shown). Although similar viral titers were used, hardly any surface expression and no effector function of the transferred TCR were detected in L-tcr-transduced T lymphocytes. In contrast, the MP-tcr-transduced PBL bulk culture strongly expressed TCR-26 and responded to RCC-26 tumor cell stimulation with cytokine secretion and cytotoxicity.
The discrepancy between similar transduction efficiency and integration rates on the one hand and different transgene expression on the other is most likely ascribed to the different cisregulatory elements of the two retroviral vectors. The strongest activating effect in the MP71 vector can be attributed to the modified 5Ј-untranslated region, originating from the murine embryonic stem cell virus (MESV) (Grez et al., 1990) . This leader sequence contains an artificial splice acceptor site complementing the retroviral splice donor site. In addition, all start codons have been removed from within the leader sequence. Consequently, the ATG of the transgene is the first start codon 3Ј of the promoter (Hildinger et al., 1999) . Moreover, the MPSV long terminal repeat (LTR) promoter and enhancer elements by themselves improve transgene expression in T lymphocytes (Schambach et al., 2000; Engels et al., 2003) and lymphohematopoietic cells (Baum et al., 1995; Hildinger et al., 1998) . The MP71-based vectors differ from the related MSCV vectors (Hawley et al., 1994) in the U3 region of the 3Ј LTR. The MP71 vector carries the MPSV U3 region (Schambach et al., 2000) . In contrast, MSCV vectors contain the respective PCC4-embryonal carcinoma cell-passaged myeloproliferative sarcoma virus (PCMV) region (Hilberg et al., 1987; Hawley et al., 1994) . Furthermore, MSCV vectors contain a hybrid leader sequence of MESV and LNCX origin, whereas the leader of MP71 vectors is solely of MESV origin. Finally, the introduction of the woodchuck hepatitis virus posttranscriptional regulatory element (PRE) into the MP71 vectors accounts for a further increase in the level of transgene expression (Zufferey et al., 1999) . The LXSN vector we have used in this comparison is a basic, entirely MLV-based vector. Several advanced vectors based on LXSN have been described, including grafting of T lymphocytes with antigen receptors (MFG-based pMX [Fujio et al., 2000; Kessels et al., 2000] and pBullet [Willemsen et al., 2000] ). They were not included in our study. However, data on GFP expression by MP71 and pBullet revealed higher transgene expression rates in MP71-transduced cells (our unpub- lished results). Taken together, the stronger cis-regulatory elements of MP-tcr in comparison with those of L-tcr lead to superior TCR expression, as shown at the transcriptional level by RT-PCR analysis and at the translational level by flow cytometric analysis of TCR-26 cell surface expression. The strong transgene expression by MP-tcr is of particular relevance because (1) the amount of TCR on the cell surface critically determines the functionality of the gene-modified T cell (Labrecque et al., 2001) and (2) a high level of TCR expression is achieved at a low multiplicity of infection (MOI), thereby potentially reducing the risk of insertional mutagenesis (Hacein-Bey-Abina et al., 2003; Fehse et al., 2004) .
The MP-tcr vector is superior to the L-tcr vector not only regarding the level of TCR-26 expression, but also regarding the duration of TCR-26 expression. This is an indispensable prerequisite for the generation of a sufficient number of TCR-redirected T lymphocytes for adoptive transfer into patients. In contrast to the stable TCR-26 expression by MP-tcr transduction, L-tcr-transduced PBLs gradually lost expression over time. Genomic DNA PCR analysis of transduced PBLs showed that the number of integrated viral genomes remained similar for both vectors over time, indicating that the decrease in TCR-26 expression in L-tcr transduced cells is due to lower expression rates, probably induced by gene silencing through methylation of the MLV LTR (Jahner et al., 1982; Challita and Kohn, 1994; Wang et al., 1998) .
So far, the majority of genetically engineered tumor-reactive T lymphocytes have been endowed with TCRs recognizing melanoma-associated antigens (Clay et al., 1999; Schaft et al., 2003) . Furthermore, effector functions of TCR-redirected human PBL bulk cultures have so far been described only for mel- anoma-associated gp100 specificity (Morgan et al., 2003 ). Here we demonstrate for the first time that RCC tumor cell-specific CTLs can be generated by the transfer of antigen-specific TCR into PBLs of healthy donors. We proved the functionality of the TCR-26-redirected PBLs, using unsorted bulk cultures of MP-tcr-transduced T lymphocytes. After TCR gene transfer the PBLs of healthy donors gained HLA-A2-restricted, RCC-specific effector functions comparable in magnitude to those of the original TIL clone. In contrast, using the L-tcr vector the expression levels were not sufficiently high to induce T effector function by RCC-26 cell stimulation. Notably, in many previous studies with MLV-derived vectors, only enriched or cloned TCR-transduced T cells were investigated, indicating a low TCR expression level by MLV vectors also in other systems (Clay et al., 1999; Cooper et al., 2000; Heemskerk et al., 2003) . Similar results have been also described in a study using a chimeric antibody receptor .
In conclusion, we have demonstrated that PBLs of healthy donors can be redirected toward tumor antigens by specific TCR gene transfer. Using an optimized retroviral vector, we generated PBLs that are specific for an RCC tumor antigen and exert effector functions of similar strength and specificity as observed for the CTL clone that expresses the TCR endogenously. The antigen recognized by the transduced TCR-26 is unknown. Antigen identification requires significant numbers of T cells, which are often not achieved in RCC investigations. The described approach provides an important tool with which to identify this tumor antigen, as well as those of other TIL clones, where long-term T cell clones cannot be established. It can be envisioned that small repertoires of T cells bearing transgenic TCR to redirect their specificity toward tumors or viruses will be used in adoptive T cell therapy.
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